| Description | iMDK quarterhydrate is a potent PI3K inhibitor that inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate synergistically inhibits non-small cell lung cancer (NSCLC) with MEK inhibitors without harming normal cells and mice. |
| In vitro | 向H441肺腺癌细胞施用iMDK（50-500 nM）四水合物72小时，能够剂量依赖性地抑制AKT磷酸化。相反，iMDK四水合物显著增强了p-ERK[1]的活性。 |
| In vivo | 通过腹腔注射100 μl iMDK（（9 mg/kg/天））以及口服给药PD0325901（5 mg/kg）在异种移植小鼠模型中有效减少了肺肿瘤生长[1]。 |
| molecular weight | 376.4 |
| Molecular formula | C21H13FN2O2S |
| CAS | 881970-80-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 3.76 mg/mL (10 mM), Sonication is recommended. |
| References | 1. Naomasa Ishida, et al. A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor. Exp Cell Res. 2015 Jul 15;335(2):197-206. |
| Citations | 1. Wan Z, Bai X, Wang X, et al.Mgp High‐Expressing MSCs Orchestrate the Osteoimmune Microenvironment of Collagen/Nanohydroxyapatite‐Mediated Bone Regeneration.Advanced Science.2024: 2308986. |